AIMイムノテック (AIM ImmunoTech)、膵臓がん治療を目的としたアストラゼネカ (AstraZeneca) のImfinzi® (デュルバルマブ) との併用によるAmpligen® (リンタトリモド) を評価する第Ib/II相試験の登録開始を発表
January 10, 2024 18:48 ET
|
AIM ImmunoTech Inc.
オランダ、ロッテルダムのエラスムス医療センター (Erasmus Medical Center) で、間もなく最初の登録および最初の被験者への投与を予定 経営陣による同発表とその意義についての説明は動画を参照されたい。 フロリダ州オカラ発, Jan. 11, 2024 (GLOBE NEWSWIRE) -- AIMイムノテック (AIM ImmunoTech Inc.) (NYSE...
AIM ImmunoTech 宣布开展评估 Ampligen® (rintatolimod) 与 AstraZeneca 的 Imfinzi® (durvalumab) 联合用药治疗胰腺癌疗效的 1b/2 期研究的开放招募
January 10, 2024 18:48 ET
|
AIM ImmunoTech Inc.
首次招募和首例受试者用药预计将很快将在荷兰罗特丹的 Erasmus Medical Center 进行 管理层在以下视频中对本公告及其意义进行了讨论，视频链接为：视频 奥卡拉，佛罗里达州, Jan. 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.（美国 NYSE：AIM）（简称“AIM”或“公司”）今日宣布，在 Erasmus...
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
January 10, 2024 08:45 ET
|
AIM ImmunoTech Inc.
First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands Management discusses the announcement and what this means here: video OCALA, Fla.,...
AIMイムノテック (AIM ImmunoTech)、2つの重要な米国特許を取得し、Ampligen®の知的財産を強化
November 28, 2023 13:24 ET
|
AIM ImmunoTech Inc.
癌･ME/CFS治療薬Ampligenの米国における独占権を2039年まで延長 経営陣が特許の取得とその意味について簡単な動画で説明している。 こちら フロリダ州オカラ発 , Nov. 29, 2023 (GLOBE NEWSWIRE) -- AIMイムノテック (AIM ImmunoTech Inc.) (NYSE American: AIM) (「AIM」または「同社」)...
AIM ImmunoTech 获得两项重要美国专利，增强了 Ampligen® 的知识产权资产实力
November 28, 2023 13:24 ET
|
AIM ImmunoTech Inc.
Ampligen 治疗癌症和肌痛性脑脊髓炎 (ME)/慢性疲劳综合征 (CFS) 的某些美国独家权利延长至 2039 年 管理层在一段简短的视频中讨论了专利的颁发及其意义：点击此处 佛罗里达州奥卡拉, Nov. 29, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American:...
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
November 27, 2023 21:00 ET
|
AIM ImmunoTech Inc.
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 28, 2023 ...
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
November 27, 2023 09:05 ET
|
AIM ImmunoTech Inc.
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 27, 2023 ...
AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
November 21, 2023 12:00 ET
|
AIM ImmunoTech Inc.
No severe adverse events reported to date Topline data expected as early as Q1 2024 OCALA, Fla., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”)...
AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
November 15, 2023 07:30 ET
|
AIM ImmunoTech Inc.
– Highlights continued execution across Ampligen® clinical development programs – Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024 – Will...
AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer
November 14, 2023 10:00 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of results from the Phase 1 study at Roswell Park...